Status:

COMPLETED

Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors

Lead Sponsor:

University of Michigan Rogel Cancer Center

Conditions:

Neuroendocrine Tumors

Eligibility:

All Genders

18+ years

Phase:

EARLY_PHASE1

Brief Summary

The goal of this exploratory study is to test whether \[18F\]3F-PHPG can be used reliably to map the locations of tumors in patients with neuroendocrine tumors. If so, the results of this study will b...

Detailed Description

Subjects enrolled in this study will be recruited from the population of adult patients with neuroendocrine tumors, including pheochromocytoma and paraganglioma, being treated at the University of Mic...

Eligibility Criteria

Inclusion

  • Current neuroendocrine tumor diagnosis
  • Able to lie flat for 60 minutes
  • Provision of informed consent

Exclusion

  • Pregnancy or lactation
  • Claustrophobia
  • Inability to lie flat for 60 minutes
  • Currently taking medications that may alter PET scans of neuroendocrine tumors with these tracers, including any of the following:
  • Tricyclic antidepressants, which inhibit the norepinephrine transporter: desipramine, amitriptyline, imipramine
  • Cold medications containing the sympathomimetic amines: phenylephrine, phenylpropanolamine, pseudoephedrine
  • Nasal decongestants (some use phenylephrine as the active agent)
  • Cocaine (which inhibits the norepinephrine transporter)
  • Tetrabenazine (Xenazine), which inhibits the VMAT2 transporter
  • Monoamine oxidase inhibitors (MAOI)
  • Some antihypertensive drugs: reserpine, labetalol, α-methyldopa, clonidine

Key Trial Info

Start Date :

October 19 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 31 2024

Estimated Enrollment :

32 Patients enrolled

Trial Details

Trial ID

NCT04510311

Start Date

October 19 2020

End Date

December 31 2024

Last Update

January 10 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Michigan Rogel Cancer Center

Ann Arbor, Michigan, United States, 48109